Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 7 Sep - Newspaper Publication for Notice of 32nd Annual General Meeting.
Source: Bse
Lincoln Pharmaceuticals Limited (LINCOLN)
Small CapPharma stocks · Small cap · NSE
Lincoln Pharmaceuticals Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers.
Data qualityFresh enough for analysisQuote updated 19 Oct, 03:31 pm ISTDetails
Quote19 Oct, 03:31 pm IST
Base fundamentals06 Oct 2026 · screener
Latest result13 Aug, 11:46 am IST
Score20 Oct, 04:30 am IST · v4.3-runtime-valuation
Tags02 May 2026
Coverage14/14 · 100%
Valuation2026-07-20 · Rf 6.8% · Pharma P/E 33.5 (n=187)
Technical timing lens
Trend score and candlestick chart
57NeutralSMA20 -7.4% / mo · MACD − · sector +3.8pp vs Nifty 500 (3M)
Stock trend: 29
Sector RS: 98
Sector 3M: -1.8% vs Nifty 500 -5.6%
Pharma FPI tailwindFlow only
FPI equity flow was positive in both fortnights, but the sector index is below its 100-session average. View sector evidence
Technical chart
LINCOLND candles · FIT view-11.6%Latest close ₹535.35 on 2026-10-19
Bar
-1.9%
RSI
31
MACD hist
-2.62
52W pos
29%
2026-10-19O ₹545.60H ₹550.00L ₹530.65C ₹535.35Vol 19,687 sh
Up bar
Down bar
EMA 20
EMA 50
Volume + 20D avg
Result date
RSI(14)
MACD / signal
Market context
Relative performance and chart statistics
Adjusted completed-session prices, rebased to 100
LINCOLNNifty PharmaNifty 500
- LINCOLN
- -10.4%
- Nifty 500
- -5.6%
- Nifty Pharma
- -1.5%
- Vs Nifty 500
- -4.8 pp
Chart stats
19 Oct 2026- From 52W high
- -30.5%
- 52W range position
- 29%
- ATR (14)
- 3.7%
- Volume vs 20D
- 0.76x
- Avg traded value
- ₹1.5 Cr
- 20D price channel
- ₹526.3 - ₹612
₹770
₹440 - ₹770
₹19.8
Latest completed session
20-session average
22.9% annualized volatility
Research snapshot
What the evidence says now
Mixed fundamentals, management evidence is still limited to a financial-only Trust Lite signal, price trend is neutral, and recent execution is mixed.
Suggested next step
Research, do not rush
The evidence is not strongly aligned. Compare peers and wait for a cleaner setup.
U-Score
Legacy · FAIR VALUE57
Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.
Latest result
Average47
Revenue +14.9% · PAT +28.6% YoY
Technical
Neutral57
Price trend and sector-relative-strength timing.
Valuation
Legacy model+32.2%
Legacy margin-of-safety estimate; the revised evidence label remains in shadow validation.
Trust
Limited evidence75
Financial-only signal; management claim evidence is not sufficient yet.
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Financials
Fundamentals, quarterly history, margins, returns and balance-sheet evidence
Latest result
Quarter ended 30 Jun 2026
Average · 47/100margin compression · Rev +15% YoY · PAT +29% YoY · operating leverage
Filed 13 Aug 2026
Open results browser →| Metric | This quarter | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹177 Cr | +14.9% | -5.3% |
| EBITDA | ₹27 Cr | +12.5% | +8.0% |
| Operating margin | 15.0% | +0 bps | +200 bps |
| PAT | ₹36 Cr | +28.6% | +200.0% |
| PAT margin | 20.3% | +216 bps | +1392 bps |
NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.
Fundamentals
Valuation
- P/E
- 11.80
- P/B
- 1.50
- EV/EBITDA
- 9.83
- Market Cap
- 1136.00Cr
Profitability
- ROE
- 12.30%
- ROCE
- 16.30%
- ROA
- 10.79%
- Dividend Y
- 0.32%
Growth (CAGR)
- Revenue 5Y
- 10.00%
- EPS 5Y
- 7.00%
- Revenue 3Y
- 10.00%
- EPS 3Y
- 7.00%
Balance Sheet
- Debt/Equity
- 0.01
- Interest Coverage
- 101.00×
- Altman Z
- 7.79
- Book Value
- 378.00
Cash Flow
- FCF Yield
- 0.70%
- FCF Positive Y
- 10/5
- OCF
- 106.00 Cr
- EPS TTM
- 48.16
Shareholding
- Promoter Hold
- 49.78%
- Promoter Pledge
- 0.00%
- Momentum 52W
- 38%
Financial History
Updated 18/10/2026
Revenue
₹ CrLatest: 177-5.3% vs prev
Net Profit
₹ CrLatest: 36.0+200.0% vs prev
ROE is shown only in the Annual view — quarterly equity data isn't published.
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Technicals
Trend interpretation, Stage 2, relative strength, volume and indicator evidence
Daily technical trend read
Mixed signalsSignals are conflicting — long-term trend down. RSI 31. Wait for confirmation.
- Price below SMA200 (long-term downtrend) — short-term bounces likely countertrend.
- SMA20 falling (~8.0% over last month) — short-term momentum negative.
- RSI(14) at 31 — rising, no extreme reading.
- MACD below signal but histogram contracting — bearish momentum easing.
- 30% off 52W high · 22% above 52W low.
Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.
Nifty 500 leadership
Relative Strength & Trend Stage
56
RS percentile
Stage 4 Downtrend
1M return
-11.5%
3M return
-10.4%
6M return
-12.2%
1Y return
+1.4%
RS 1D
0
RS 20D
-4
Sector rank
#1
Industry rank
#17
Stage evidence
- Price is 12.8% below the 30-week proxy.
- The 50-DMA is below the 30-week proxy and its slope is falling -0.9%.
- Both 3-month and 6-month returns are negative.
50-DMA
price below
200-DMA
price below
Sector
leading
Industry
leading
Relative-strength line vs Nifty 500 (base 100)
262 observations
19 Oct 2026Value 102.67-0.87%
RS vs Nifty 500103
Valuation & peers
U-Score 57 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Valuation & peers
U-Score 57 · legacy U-Score band FAIR VALUE · valuation evidence and comparable companies
Deep Value
Fundamental score breakdown
U band · FAIR VALUEValuation24/30
Growth8/25
Quality4/20
Balance Sheet12/15
Cash Flow4/10
Piotroski
8/9 (+5)
Penalties
0
Raw sum
57
Why this score?
Top U-Score contributors and drags from the latest stored fundamentals.
57/100 · legacy band FAIR VALUE
Positive drivers
- Piotroski is strong at 8/9.
- Fair-value margin of safety is positive at 32.2%.
- Valuation contributes 24/30 to the score.
Main drags
- Quality is weaker at 4/20; verify the latest quarterly trend.
- Growth is weaker at 8/25; verify the latest quarterly trend.
- Cash flow is weaker at 4/10; verify the latest quarterly trend.
Sector valuation model
Healthcare valuation: PE/EVEBITDA with regulatory and pipeline checks
Healthcare valuation needs both earnings quality and regulatory/pipeline context.
Primary lens
PE and EV/EBITDA adjusted for product mix and R&D/pipeline quality.
Secondary checks
USFDA risk, launch pipeline, margin trend, domestic vs export mix.
Main risk check
Regulatory setbacks or one-off product cycles can distort valuation.
PE
11.8
PB
1.5
EV/EBITDA
9.8
ROE
12.3%
ROCE
16.3%
FCF Yield
0.7%
Debt/Equity
0.0
MoS
+32.2%
Score movement
Stored run vs live recompute
This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.
Stored run: 20 Oct 2026
v4.3-runtime-valuation
Final score
57
Previous: 57
Legacy U-Score band
FAIR VALUE
Previous: FAIR VALUE
Margin of safety
+32.2%
Previous: +32.2%
Score history
12 stored score snapshots. Latest stored move: +0 points.
20 Oct 2026
v4.3-runtime-valuation
57
57
57
57
57
57
57
57
57
57
57
57
Factor attribution
No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Modelled fair value
Graham Number
₹640
+16.4% MoS
Growth-justified P/E
16.4
Growth-justified Value
₹789.82
+32.2% MoS
PEG
1.69
Comparable companies
Peers
Business-comparable peers in Pharma — ranked by industry, sub-sector, theme-tag overlap, market cap, and U-Score similarity. Green cells mark the best available peer metric in this table.
Ticker
Name
Why peer
Score
PE
ROE
MoS
Verdict
KILITCH
Small
Kilitch Drugs (India) Limited
Healthcare Services
match 165
50
27.5
10.6%
+43%
FAIR VALUE
TTKHLTCARE
Small
TTK Healthcare Limited
Healthcare Services
match 165
46
18.6
6.3%
+56%
FAIR VALUE
THEMISMED
Small
Themis Medicare Limited
Healthcare Services
match 164
18
—
0.4%
-2440%
OVERVALUED
SURAKSHA
Small
Suraksha Diagnostic Limited
Healthcare Services
match 162
52
48.3
14.2%
+4%
FAIR VALUE
ZIMLAB
Small
Zim Laboratories Limited
Healthcare Services
match 161
17
200.0
1.6%
-6584%
OVERVALUED
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business, management & trust
Growth engines, risks, management commitments and evidence-backed delivery
Business and thesis
Issuer presentation review pending
Lincoln Pharmaceuticals Limited operates in Hospitals / Diagnostics, within the Pharma sector. Use the latest filing and company disclosures below to verify its revenue mix and current business drivers. The structured result feed currently covers the quarter ended 30 Jun 2026. Investor presentations and earnings-call PDFs will be added as issuer-backed evidence before management claims appear here.
Trust Score
75Limited evidence · low confidenceTrust Lite
Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.
Limited evidence: Claim history is still being built. It ranks around the 78th percentile of the scored universe and 69th percentile within Pharma. Main check: financial discipline is weak at 50/100.
This is a financial-behaviour screen, not a claim-tested management reliability verdict.
Computed 05 Sept 2026
management-trust-v1
39 docs text-extracted · 4 concalls text-extracted
Score band
Limited evidence
Financial behaviour is scored, but management claims do not yet have enough outcome checks.
Relative rank
78th percentile
overall median 67 · Pharma: 69th pctile, median 70 · Small: 80th pctile, median 66
Evidence depth
Financial-only
39 documents have extracted text, but claim history is not strong enough yet.
Claim delivery
Outcome history still building
0 claims extracted · No contradicted claim yet
How to read this Trust Score
Limited evidence · low confidenceWhat it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Can support position sizing if valuation and trend also agree.
Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.
Forensic breakdown
Read low sub-scores as due-diligence warnings, not automatic sell signals.
Promoter
78
strong · holding, pledge, alignment
Cash flow
77
strong · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
50
watch · capital discipline
Results
70
acceptable · quarterly consistency
Trust positives
- ▸Promoter pledge is zero.
- ▸FCF yield is positive at 0.6%.
- ▸10 years of positive FCF.
- ▸Debt/equity is 0.01.
Trust risks
- ▸ROCE trend is -2%.
- ▸2 older quarters in the 8-quarter window had PAT decline worse than 25% YoY.
Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.
Continue researching Lincoln Pharmaceuticals Limited
Important announcements & filings
Latest exchange and company disclosures found within the past two years.
Open source ↗
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 14 Aug - We enclosed herewith the copies of newspaper intimation with respect to the unaudited (standalone & Consolidated) Financial Results of the Company for the Quarter Ended …
Source: Bse
Announcement
Announcement under Regulation 30 (LODR)-Newspaper Publication 29 May - We enclosed herewith the copies of published newspaper advertisement with respect to Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and …
Source: Bse
Announcement
Corporate Action-Board approves Dividend 28 May - Board approved audited FY26 results and recommended 18% dividend of Rs 1.80 per share.
Source: Bse
Annual report
Annual Report 2026
Source: Bse
Annual report
Annual Report 2025
Source: Bse
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.